產品詳情
簡單介紹：
Anti-LRFN1抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-LRFN1抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-LRFN1
Cat. Number:
Anti-LRFN1抗體KL-12141R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
LRFN1 is a 771 amino acid single-pass type I membrane protein that belongs to the LRFN family. Containing a fibronectin type-III domain, an Ig-like (immunoglobulin-like) domain, a LRRCT domain, a LRRNT domain and seven LRR (leucine-rich) repeats, LRFN1 is thought to promote neurite outgrowth in hippocampal neurons and is involved in the regulation and maintenance of excitatory synapses. LRFN1 forms heteromeric Anti-LRFN1抗體complexes with LRFN2, LRFN3, LFRN4 and LFRN5, but does not have the ability to form homomeric complexes across cell junctions of adjacent cells like other LRFN family members. The PDZ-binding motif of LRFN1 is required for neurite outgrowth promotion and for SAP 97-, NE-dlg- and PSD-95-binding. LRFN1 is encoded by a gene located on human chromosome 19q13.2 and mouse chromosome 7 A3.
Also known as:
Leucine rich repeat and fibronectin type III domain containing 1; Leucine rich repeat and fibronectin type III domain containing protein 1;Anti-LRFN1抗體 Leucine-rich repeat and fibronectin type III domain-containing protein 1; LRFN 1; lrfn1; LRFN1_HUMAN; SALM 2; SALM2; Synaptic adhesion like molecule 2; Synaptic adhesion-like molecule 2.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Pig, Cow, Sheep, .
●
Immunogen: KLH conjugated syntheticAnti-LRFN1抗體 peptide derived from human LRFN1.
●
Predicted Molecular Weight: 79kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-LRFN1抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
